Premium
Synergistic inhibitory effect of high‐intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma
Author(s) -
Paparel Philippe,
Curiel Laura,
Chesnais Sabrina,
Ecochard Rene,
Chapelon JeanYves,
Gelet Albert
Publication year - 2005
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2005.05420.x
Subject(s) - medicine , chemotherapy , prostate cancer , high intensity focused ultrasound , urology , prostate , paclitaxel , adenocarcinoma , ultrasound , stage (stratigraphy) , oncology , cancer , radiology , biology , paleontology
OBJECTIVE To evaluate the therapeutic effect of high‐intensity focused ultrasound (HIFU) combined with chemotherapy (paclitaxel + estramustine) on AT2 Dunning adenocarcinoma, as no satisfactory treatment for localized prostate cancer is available for patients with a poor prognosis, e.g. stage T3, a high Gleason score, or a prostate‐specific antigen level of >15 ng/mL. MATERIALS AND METHODS Forty‐one Dunning AT2 tumour‐bearing Copenhagen rats were divided into four groups, i.e. control, chemotherapy, HIFU, and chemotherapy + HIFU (the last three treated for 1 week). The growth in tumour volume was recorded for 3 weeks, the point at which tumour volume was considered to have doubled (doubling time). The growth curves of each group were plotted and evaluated statistically. RESULTS At 30 days of follow‐up the distributions of tumour volume with treatment group were significantly different ( P < 0.001); volumes were significantly greater in the control than in the chemotherapy‐only or in the HIFU‐only group (both P = 0.006). The greatest difference was between the chemotherapy + HIFU and the control group. The tumour doubling times were 13.2 days for HIFU‐only, 31.2 days for chemotherapy + HIFU and 7.7 days for the controls. CONCLUSION These results suggest that this combined therapy could be useful for treating patients with high‐risk prostate cancer.